Biopharmaceutical company Antengene Corporation Limited said on Sunday that the results from a preclinical study jointly conducted with Karyopharm Therapeutics and University of Georgia College of Veterinary Medicine has been published in a paper titled "selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo."
Published in Antiviral Research, which is a scientific journal in virology, the study showed that the nuclear export protein exportin-1 (XPO1) plays a direct role in severe acute respiratory syndrome coronavirus 2 infections and the pathogenesis of coronavirus disease 19 and the selective oral inhibitor of XPO1, selinexor, has potent anti-SARS-CoV-2 activity both in vitro and in vivo, added the partnership.
Based on the results from this study and other existing evidence, XPO1 has a direct role in SARS-CoV replication and pathogenesis and is responsible for the nuclear export of certain SARS-CoV proteins that evades innate immunity, revealed the company.
The partners disclosed selinexor inhibits inflammatory cytokine expression by lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (PBMCs). Elevated level of inflammatory cytokine is a key etiological feature and cause of death in patients infected with SARS-CoV-2. The selinexor can significantly lower the ex vivo inflammatory cytokine release by LPS-stimulated human PBMCs.
In addition, Selinexor is the first and only oral SINE compound approved by the FDA and is the first drug approved for the treatment of both MM and DLBCL, concluded the company.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review